Ping earned his BS in Biotechnology at Peking University, Beijing, China. He got his PhD in Cancer Biology from Weill Medical College of Cornell University. Ping’s research interest focus on understanding the mechanism of antiandrogen resistance in advanced prostate cancer and developing novel therapeutic approaches to overcome resistance. Ping’s recent work revealed a novel mechanism of antiandrogen resistance mediated by increased lineage plasticity, which is enabled by the loss of TP53 and RB1 function, and due to activation of SOX2. He is now investigating the molecular mechanism of SOX2 transcriptional activation and its downstream signaling molecules, in an effort to develop novel therapeutic targets to overcome resistance.